Feature|Videos|January 2, 2025
Final Thoughts
The future of CAR T-cell therapies will continue to improve as they expand to other patients in need.
Advertisement
Episodes in this series
The panelists provide their closing thoughts on CAR T-cell therapies and what they look forward to as these therapies become popular beyond cancer, extending to autoimmune diseases as well. There is hope to remove manufacturing bottleneck so patient demand and access can improve.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Shionogi Inc. Awarded $482 Million Contract with U.S. Government to Enhance National Preparedness for Drug-Resistant Bacterial Threats
2
Pharmaceutical Executive Daily: China Approves Amgen's Tarlatamab for Previously Treated Extensive-Stage Small Cell Lung Cancer
3
New Study Reveals Genetic Predictors for GLP-1 Weight Loss and Side Effects
4
Q&A: Supply Chain Fallout From Iran War, Tariff Uncertainty
5